The metabolic syndrome and left ventricular hypertrophy - The influence of gender and physical activity

Blood Pressure

Volumn 21, Issue 3, 2012, Pages 153-160

  Halldin, Mats ^a   Fahlstadius, Per ^a   De Faire, Ulf ^a,b   Vikström, Max ^a   Hellénius, Mai Lis ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cross sectional; gender; hypertension; left ventricular hypertrophy; metabolic syndrome; physical activity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; PREVALENCE; RISK FACTORS; SEX FACTORS; SWEDEN; WAIST CIRCUMFERENCE;

EID: 84860842264     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2012.641267     Document Type: Article

References (54)

1. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Defi nition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute. Circulation. 2004;109: 433-438.
2. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-414. (Pubitemid 46135879)
3. Halldin M, Rosell M, de Faire U, Hellé nius ML. The metabolic syndrome: Prevalence and association to leisure-time and work-related physical activity in 60-year-old men and women. Nutr Metab Cardiovasc Dis. 2007;17:349-357. (Pubitemid 46880264)
4. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala KD. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med. 2004;164:1066-1076. (Pubitemid 38668985)
5. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-695. (Pubitemid 39233630)
6. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defi ned metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52: 1210-1214. (Pubitemid 36523358)
7. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med. 2006;119:812-819. (Pubitemid 44415613)
8. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-414. (Pubitemid 46135879)
9. Reilly MP, Rader DJ. The metabolic syndrome: More than the sum of its parts? Circulation. 2003;108:1546-1551. (Pubitemid 37187778)
10. Artham SM, Lavie CJ, Milani RV, Patel DA, Verma A, Ventura HO. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009;52:1 53-167.
11. Rodrigues SL, Baldo MP, Sá Cunha R, Angelo LC, Pereira AC, Krieger JE, Mill JG. Anthropometric measures of increased central and overall adiposity in association with echocardiographic left ventricular hypertrophy. Hypertens Res. 2010;33:83-87.
12. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
13. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004;93:40-44. (Pubitemid 38028620)
14. Sundstr öm J, Arnlöv J, Stolare K, Lind L. Blood pressureindependent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: A population based study. Heart. 2008;94:874-878. (Pubitemid 351914697)
15. Cuspidi C, Meani S, Valerio C, Sala C, Fusi V, Zanchetti A, Mancia G. Age and target organ damage in essential hypertension: Role of the metabolic syndrome. Am J Hypertens. 2007;20:296-303. (Pubitemid 46283362)
16. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006;47:881-886. (Pubitemid 44297559)
17. Crabbe DL, Harris NK. Hypertrophy in the female heart. Curr Cardiol Rep. 2005;7:173-177. (Pubitemid 41149815)
18. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framingham Heart Study. Circulation. 2003;107:448-454. (Pubitemid 36158048)
19. Wannamethee SG, Shaper AG. Physical activity in the prevention of cardiovascular disease: An epidemiological perspective. Sports Med. 2001;31:101-114. (Pubitemid 32178873)
20. Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged Finnish men and women. Int J Obes (Lond). 2005;29:894-902. (Pubitemid 41076228)
21. Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet. 1998;351:1603-1608. (Pubitemid 28252175)
22. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
23. Fossati P, Prencipe L, Berti G. Use of 3,5-dichloro-2- hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem. 1980;26:227-231. (Pubitemid 10164452)
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. Prineas RJ, Crow RS, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings. 2nd ed. London: Springer Verlag; 2010.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation. 2005;112:2735-2752.
27. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
28. Oberman A, Prineas RJ, Larson JC, LaCroix A, Lasser NL. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women (The Women ' s Health Initiative). Am J Cardiol. 2006;97:512-519. (Pubitemid 43190042)
29. Ferrara AL, Vaccaro O, Cardoni O, Panarelli W, Laurenzi M, Zanchetti A. Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. Nutr Metab Cardiovasc Dis. 2003;13:126-132. (Pubitemid 38561073)
30. de Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, Howard BV. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study. Nutr Metab Cardiovasc Dis. 2009;19:98-104.
31. Grassi G, Seravalle G, Quarti-Trevano F, Dell' O ro R, Bombelli M, Mancia G. Metabolic syndrome and cardiometabolic risk: An update. Blood Press. 2009;18:7-16.
32. de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Ibsen H, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: The LIFE study. J Hum Hypertens. 2007;21:625-632. (Pubitemid 47162725)
33. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A, et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med. 2005;257:454-460. (Pubitemid 40613071)
34. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens. 2008;26: 1602-1611.
35. Cuspidi C, Sala C, Zanchetti A. Metabolic syndrome and target organ damage: Role of blood pressure. Expert Rev Cardiovasc Ther. 2008;6:731-743.
36. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A metaanalysis. Am J Hypertens. 2003;16(11 Pt 1):895-899. (Pubitemid 37315486)
37. Mul é G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, et al. Infl uence of metabolic syndrome on hypertensionrelated target organ damage. J Intern Med. 2005;257: 503-513. (Pubitemid 40776510)
38. Azevedo A, Bettencourt P, Almeida PB, Santos AC, Abreu- Lima C, Hense HW, Barros H. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities-cross-sectional study of the general population. BMC Cardiovasc Disord. 2007;7:17.
39. Grandi AM, Maresca AM, Giudici E, Laurita E, Marchesi C, Solbiati F, et al. Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens. 2006;19:199-205. (Pubitemid 43350174)
40. Santra S, Basu AK, Roychowdhury P, Banerjee R, Singhania P, Singh S, Datta UK. Comparison of left ventricular mass in normotensive type 2 diabetes mellitus patients with that in the nondiabetic population. J Cardiovasc Dis Res. 2011;2: 50-56.
41. Davis CL, Kapuku G, Snieder H, Kumar M, Treiber FA. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci. 2002;324:72-75. (Pubitemid 34851729)
42. Arnl öv J, Lind L, Sundstr öm J, André n B, Vessby B, Lithell H. Insulin resistance, dietary fat intake and blood pressure predict left ventricular diastolic function 20 years later. Nutr Metab Cardiovasc Dis. 2005;15:242-249. (Pubitemid 41190980)
43. Devereux RB, Roman MJ, Paranicas M, O' G rady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The strong heart study. Circulation. 2000; 101:2271-2276. (Pubitemid 30317129)
44. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102-107. (Pubitemid 32050443)
45. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: The HyperGEN study. J Hypertens. 2002;20:323-331. (Pubitemid 34913799)
46. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
47. Lichtman SW, Pisarska K, Berman ER, Pestone M, Dowling H, Offenbacher E, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med. 1992;327:1893-1898. (Pubitemid 23006963)
48. Dishman RK, Darracott CR, Lambert LT. Failure to generalize determinants of self-reported physical activity to a motion sensor. Med Sci Sports Exerc. 1992;24:904-910.
49. Ainsworth BE. How do I measure physical activity in my patients? Questionnaires and objective methods. Br J Sports Med. 2009;43:6-9.
50. Macfarlane P.W. Is electrocardiography still useful in the diagnosis of cardiac chamber hypertrophy and dilatation Cardiol. Clin. 2006 401-411.
51. Macfarlane PW. Is electrocardiography still useful in the diagnosis of cardiac chamber hypertrophy and dilatation? Cardiol Clin. 2006;24:401 - 411, ix. 51. Pewsner D, J üni P, Egger M, Battaglia M, Sundstr öm J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: Systematic review. BMJ. 2007;335:711.
52. Ang D, Lang C. The prognostic value of the ECG in hypertension: Where are we now? J Hum Hypertens. 2008;22: 460-467. (Pubitemid 351877733)
53. S haper AG, Wannamethee G, Walker M. Physical activity, hypertension and risk of heart attack in men without evidence of ischaemic heart disease. J Hum Hypertens. 1994;8: 3-10. (Pubitemid 24052180)
54. Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet. 1998;351:1603-1608. (Pubitemid 28252175)